에이프릴바이오

397030KOSDAQ자연과학 및 공학 연구개발업

53.5 / 100

Reference Date: 2026-07-24

Financial Score18.5 / 40

News Sentiment17.9 / 25

Momentum2.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 33.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

April Bio is a research and development-focused company established in 2013, leveraging human antibody production and protein half-life extension technologies to develop antibody therapeutics and sustained recombinant protein drugs. Utilizing its core HuDVFab library and SAFA platform technologies, the company focuses on developing treatments for autoimmune and inflammatory diseases, generating revenue through global licensing agreements with pharmaceutical companies under its RIPCO business model.

Number of Employees

27people

Average Salary

201.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

6.45Industry Average 2.520.0Point

2.6x industry avg (risky)

ROE

-10.39Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

0.27Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼92.1% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲41.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.9% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 7Neutral 3Negative 1Average Sentiment Score 71.8

Positive
에이프릴바이오, 큐리진서 이중표적 siRNA 도입…대사질환 파이프라인....
에이프릴바이오가 큐리진으로부터 대사질환 치료제 개발에 필요한 핵심 기술을 확보하여 신약 개발 가능성이 높아졌다.
Positive
에이프릴바이오, '리맵' 후보 확장에 큐리진 지분 투자
에이프릴바이오의 큐리진 지분 투자로 리맵 프로젝트 확장이 가속화되어 긍정적인 시장 반응 예상.
Positive
에이프릴바이오, 큐리진 2대 주주로… RNA 치료제 시장 본격 진출
에이프릴바이오의 큐리진 지분 인수로 RNA 치료제 시장 진출이 가속화되어 긍정적인 투자 전망을 제공합니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 26,550Won52-week high 73,30052-week low 19,400

1-month return0.0Point

1m -33.12% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

14 totalPositive 9Neutral 5Negative 0

Positive증권발행결과(자율공시) (제3자배정 유상증자-의결권부전환우선주)2026-07-23
Neutral증권발행결과(자율공시) (제3자배정)2026-07-23
Neutral증권발행결과(자율공시) (제3자배정-무의결권부전환우선주)2026-07-23
Positive[기재정정]주요사항보고서(유상증자결정)2026-07-23
Positive[기재정정]경영권변경등에관한계약체결2026-07-23